Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Drug Manufacturers - Specialty & Generic

Healthcare
$21.88 -0.90%

-$0.15 today

Market cap
$7.62B
Beta
1.32
P/E (TTM)
43.4
EPS (TTM)
$0.37
52W Low $7.67High $16.61

Volume 1.91M

Average 1.75M

AMRX Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Amneal Pharmaceuticals, Inc.NASDAQ: AMRX

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin widens to 18.3%

Operating margin was 18.3% in Q2 FY2026, up 3.0 pp from a year earlier. On a trailing-twelve-month basis it was 12.9%, down 0.3 pp year over year. Over 3 fiscal years it widened by 18.3 pp.

Context

  • Operating margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 5 analysts of 23.3% for the fiscal year ending Dec 2026, up from 14.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
18.3%-1.4 pp QoQ
Last fiscal yearDec 2025
14.0%+5.1 pp YoY
LTMJun 2026
12.9%-0.3 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+3.0 pp+21.6 pp+18.7 pp
1 year+5.1 pp+9.3 pp+4.2 pp
3 years+18.3 pp+12.2 pp-6.1 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
14.0%
Year-over-year change
+5.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How AMRX compares with its peers on the latest reported figures

  • AMRX's LTM Jun 2026 operating margin of 12.9% is the 5th highest of the 11 companies compared; the peer median is 11.0%.
  • Its year-over-year change of -0.3 pp is the 7th highest of 11, against a peer median of +7.5 pp.
  • Over three fiscal years its change of +18.3 pp compares with a peer median of +11.5 pp.
AMRX Competitors Peer median
Operating Margin for AMRX and competitors
Company Period LTM level YoY 3-year change
INDVIndivior Pharmaceuticals IncLTM Jun 202638.9% +18.6 pp+30.4 pp
BHCBausch Health Companies Inc.LTM Jun 202625.4% +9.0 pp+15.7 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202616.2% -10.5 pp-2.0 pp
ANIPANI Pharmaceuticals, Inc.LTM Mar 202613.4% +12.4 pp+20.3 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 202612.9% -0.3 pp+18.3 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 202611.5% +6.1 pp+27.2 pp
EBSEmergent BioSolutions Inc.LTM Mar 202610.5% +20.9 pp+30.0 pp
RDYDr. Reddy's Laboratories LimitedLTM Sep 20268.9% -11.9 pp-9.4 pp
PRGOPerrigo Company plcLTM Jun 20265.2% -1.4 pp+6.3 pp
VTRSViatris Inc.LTM Jun 2026-0.6% +17.8 pp-28.6 pp
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026-17.2% -9.2 pp+7.3 pp
Peer median (excluding AMRX) 11.0%+7.5 pp+11.5 pp

Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.09B2.21B2.39B2.79B3.02B
Cost of Revenue1.32B1.42B1.53B1.77B1.88B
Gross Profit768.97M791.46M863.87M1.02B1.14B
Gross Margin36.7%35.8%36.1%36.5%37.6%
Research & Development209.56M208.66M194.75M190.71M186.18M
Selling, General & Admin365.5M399.7M429.68M476.44M526.83M
Operating Expenses616.26M886.39M659.5M771.11M713M
Depreciation & Amortization233.41M240.18M229.4M236.19M223.57M
EBITDA401.1M440.21M500.78M439.77M603.87M
EBITDA Margin19.2%19.9%20.9%15.7%20.0%
Operating Income152.72M(94.93M)204.37M249.33M423.09M
Operating Margin7.3%-4.3%8.5%8.9%14.0%
Interest Income00000
Interest Expense136.33M158.38M210.63M258.6M241.09M
Other Income / Expenses(121.35M)(153.2M)(244.64M)(304.34M)(283.88M)
Income Before Tax31.37M(248.13M)(40.27M)(55.01M)139.21M
Pre-Tax Margin1.5%-11.2%-1.7%-2.0%4.6%
Income Tax Expense11.2M6.66M8.45M18.86M11.28M
Net Income10.62M(129.99M)(83.99M)(116.89M)72.06M
Net Margin0.5%-5.9%-3.5%-4.2%2.4%
EPS (Basic)0.07(0.86)(0.48)(0.38)0.23
EPS (Diluted)0.07(0.86)(0.48)(0.38)0.22
Weighted Avg Shares148.92M150.94M174.99M308.98M313.37M
Weighted Avg Shares (Diluted)151.82M150.94M176.14M308.98M324.81M

Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Intrinsic Alpha fair value

Locked

Current Price

$21.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.